Atara gets FDA approval to start two phase 3 studies to assess tabelecleucel in patients with EBV+PTLD

This article was originally published here

Atara Biotherapeutics has received clearance from the US Food and Drug Administration (FDA) to initiate two phase 3 clinical studies with tabelecleucel (formerly known as ATA129) in patients with rituximab-refractory Epstein-Barr virus (EBV) associated post-transplant lymphoproliferative disorder (EBV+PTLD).

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply